This was confirmed by analyzing Bax expression (Figure 4B) and activation (Figure 4C), which were enhanced in CLL cells subjected to combination treatments compared to single treatments (Figures 4B, C). Here, BAX is linked to B-cell chronic lymphocytic leukemia.